Sales successes for cancer treatments – such as Kisqali, against breast cancer, Pluvicto, against prostate cancer, and Scemblix against leukemia – contribute.
To prepare for the competition from generic drugs of the bestsellers, Novartis has made several major acquisitions in recent times, such as the purchase of Avidity Biosciences for 12 billion dollars and Tourmaline Bio for 1.4 billion dollars.
Novartis is primarily known for its medicines against cancer and autoimmune diseases. The share has risen by 18 percent on the Zurich stock exchange so far this year.
